Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 2, 2009, Pages 349-352

  Mizukami, Katsuyoshi ^a   Hatanaka, Kimitaka ^b   Tanaka, Yoshiro ^b   Sato, Shinji ^c   Asada, Takashi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Ishizaki Hospital   (Japan)

^c Tsukuba Memorial Hospital   (Japan)

Author keywords

Alzheimer's disease; Depression; Milnacipran; SNRI

Indexed keywords

AMANTADINE; DONEPEZIL; MIANSERIN; MILNACIPRAN; NICERGOLINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SULPIRIDE;

AGED; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BEHAVIORAL SCIENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION IMPROVEMENT; GERIATRIC PATIENT; HAMILTON SCALE; HUMAN; HYPOCHONDRIASIS; HYPOMANIA; INSOMNIA; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR RETARDATION; SOMATOFORM DISORDER; SUICIDAL BEHAVIOR; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENERGIC UPTAKE INHIBITORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 60049097090     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.12.019     Document Type: Article

References (27)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. (1994), American Psychietric Association, Washington, DC
2. Burke W.J., Dewan V., Wengel S.P., Roccaforte W.H., Nadolny G.C., and Folks D.G. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry 12 (1997) 519-525
3. Burns A., Jacoby R., and Levy R. Psychiatric phenomena in Alzheimer's disease, III: disorders of mood. Br J Psychiatry 157 (1990) 81-86
4. Chemerinski E., Petracca G., Sabe L., Kremer J., and Starkstein S.E. The specificity of depressive symptoms in patients with Alzheimer's disease. Am J Psychiatry 158 (2001) 68-72
5. Erlangsen A., Zarit S.H., and Conwell Y. Hospital-diagnosed dementia and suicide: a longitudinal study using prospective, nationwide register data. Am J Geriatr Psychiatry 16 (2008) 220-228
6. Folstein M.F., Folstein S., and McHugh P.R. "Mini-mental state": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 12 (1975) 189-196
7. Gonzales-Salvdor T., Lyketsos C.G., Baker A.S., Roques C., Hovanek L., Steele C.D., et al. Quality of life of patients with dementia in long-term care. Int J Geriatr Psychiatry 15 (2000) 181-189
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
9. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. Br J Psychiatry 140 (1982) 566-572
10. Jacobs M.R., Strauss M.E., Patterson M.B., and Mack J.L. Characterization of depression in Alzheimer's disease by the CERAD behavior rating scale for dementia (BRSD). Am J Geriatr Psychiatry 6 (1998) 53-58
11. Katz I.R. Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementia. J Clin Psychiatry 59 suppl 9 (1998) 38-44
12. Lim W.S., Rubin E.H., Coats M., and Morris J.C. Early-stage Alzheimer disease represents increased suicidal risk in relation to later stages. Alzheimer Dis Assoc Disord 19 (2005) 214-219
13. Lyketsos C.G., DelCampo L., Steinberg M., Miles Q., Steele C.D., Munro C., et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60 (2003) 737-746
14. Magai C., Kennedy G., Cohen C.I., and Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 8 (2000) 66-74
15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
16. Migliorelli R., Teson A., Sabe L., Petracchi M., Leiguarda R., and Starkstein S.E. Prevalence and correlates of dysthymia and major depression in Alzheimer's disease. Am J Psychiatry 152 (1994) 37-44
17. Mizukami K., Tanaka Y., and Asada T. Efficacy of milnacipran of depressive state in the patients with in Alzheimer's disease. Prog Neuro-psychopharmacol Biol Psychiatry 30 (2006) 1342-1346
18. Moret C., Charveron J., Finberg J.P.M., Couzinier J.P., and Briley M. Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24 (1985) 1211-1219
19. Petracca G.M., Chemerinski E., and Starkstein S.E. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 13 (2001) 233-240
20. Puech A., Montgomery S.A., Prost J.F., Solles A., and Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12 (1997) 99-108
21. Puozzo C., and Leonard B.E. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 11 Suppl.4 (1996) 15-27
22. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 24 (1988) 653-659
23. Taragano F.E., Lyketsos C.G., Mangone C.A., Allegri R.F., and Comesaña-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38 (1997) 246-252
24. Teri L., Reifler B.V., Veith R.C., Barnes R., White E., Mclean P., et al. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 46 (1991) 372-377
25. Tignol J., Pujol-Domenech L., Chartres J.P., Léger J.M., Plétan Y., Tonelli I., et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Arch Psychiatr Scand 97 (1998) 157-165
26. Tokuyama A., Nakamura Y., Morikawa M., Hirayama T., Kou M., Inoue Y., et al. Efficacy of eight weeks treatment with milnacipran in senile depressive disorder. Rinsho Seishin Yakuri 7 (2004) 363-370 (in Japanese)
27. Wilson K., and Mottram A. Comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 19 (2004) 754-762